Results 141 to 150 of about 24,877 (187)

Real-world outcomes after switching to faricimab in treatment-resistant diabetic macular edema: A 1-year observational study with choroidal thickness assessment. [PDF]

PLoS One
Tomemori R, Mori H, Tanaka M, Kiriishi T, Omi M, Hattori Y, Oba S, Ohnaka M, Imai H.   +8 more
europepmc   +1 more source

Refractory diabetic macular edema.

Journal of ophthalmic & vision research, 2010
openaire   +2 more sources

Long-Term Intravitreal Dexamethasone Implant Monotherapy in Naïve Patients with Diabetic Macular Edema. [PDF]

Turk J Ophthalmol
Karataş G, Çakır A, Aday Ö, Uzundede T, Kırık F, Özoğuz AM, Özdemir H, Elçioğlu MN.   +7 more
europepmc   +1 more source

Therapeutic Outcomes of Anti-VEGF Agents Versus Corticosteroids in Diabetic Macular Edema: A Comparative Review. [PDF]

Int J Mol Sci
Sanaka S, Yu M.
europepmc   +1 more source

Development of a predictive model based on aqueous cytokines data for response to anti-VEGF therapy in diabetic macular edema. [PDF]

Eye Vis (Lond)
Yang F, Gong Y, Pan X, Zhao J, Yu R, Tan L, Pazo EE, Zhang X, Li X.   +8 more
europepmc   +1 more source

Systemic-retinal inflammatory crosstalk in diabetic macular edema: correlation between hematologic indices and macular OCT-features. [PDF]

Int J Retina Vitreous
Harley O, Amelia YS, Gustianty E, Soetedjo NNM, Kartasasmita AS.   +4 more
europepmc   +1 more source

Intravitreal Fluocinolone Acetonide Implant for Diabetic Macular Edema: 2-Year Results from IDEAL, a Prospective German Observational Study.

Ophthalmologica
Ziemssen F, Kaymak H, Siebert M, Khoramnia R.   +3 more
europepmc   +1 more source

Evaluation of Spectral Domain OCT Changes Following Anti-VEGF Therapy in Diabetic Macular Edema.

J Pharm Bioallied Sci
Mandloi G, Jain A, Sharma A, Tirkey ER, Jain S.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Diabetic macular edema

Disease-a-Month, 2021
Diabetic retinopathy (DR) is a leading cause of preventable blindness world-wide. Diabetic macular edema (DME) is the most common cause of moderate vision loss in patients with diabetes. Although treatments for DME have improved significantly over the past decades, the burden of this disease remains high for patients and the healthcare system alike ...
Melissa, Ixcamey, Camille, Palma
openaire   +4 more sources

Diabetic Macular Edema

Ophthalmology, 2012
Brasil OFM, 2007, BRIT J OPHTHALMOL, V91, P761, DOI 10.1136-bjo.2006.105783; Gibran SK, 2007, OPHTHALMOLOGY, V114, P890, DOI 10.1016-j.ophtha.2006.11.026; Kim BY, 2006, AM J OPHTHALMOL, V142, P405, DOI 10.1016-j.ajo.2006.04.023; Shin HJ, 2012, GRAEF ARCH CLIN EXP, V250, P61, DOI 10.1007-s00417-011-1774-x; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15 ...
Nicola G, Ghazi, Ryan T, Scruggs, Andrew R, Batchelet, Michael W, Compton, Souha S, Allam, James, Patrie, Haytham I, Salti   +6 more
  +7 more sources